Phaseline

Companies › Noveome Biotherapeutics, formerly Stemnion

Noveome Biotherapeutics, formerly Stemnion: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Immunology; next expected readout Jun 2029.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
ST266
Biologic therapy for NEC
–Phase 1Necrotizing EnterocolitisJun 2029

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06315738ST266Phase 1Necrotizing EnterocolitisImmunologyJun 2029

From the company's SEC filings

Private offerings reported to the SEC (Form D)

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.